[10][11][12] It was approved for medical use in the European Union in 2010,[7] in the United States in 2011,[4] and in Canada in 2017.

[13] Roflumilast is indicated for the treatment of severe chronic obstructive pulmonary disease (COPD),[4] plaque psoriasis,[5][14] seborrheic dermatitis,[6] and atopic dermatitis,[5][15] It is used in the prevention of exacerbations (lung attacks) in severe chronic obstructive pulmonary disease (COPD).

[3][4][7][8][9] Common (1–10% incidence) adverse effects include diarrhea, weight loss, nausea, headache, insomnia, decreased appetite, abdominal pain, rhinitis, sinusitis, urinary tract infection, and depression.

[4][3][8][9][16] In June 2010, it was approved in the European Union for severe COPD associated with chronic bronchitis.

[7][17] In February 2011, it gained FDA approval in the United States for reducing COPD exacerbations.